





Keith William Orford - Canton, MA | Intelius



























Sign In



We found Keith William Orford in Canton, MA


Keith William Orford

                                                                           Intelius found that Keith William Orford  is  a male between 40 and 50 years old from Canton, MA.  We have connected them to
                11 addresses,
                8 phones,
                and 1 relative or associate.
         





Also Known As

Keithwillia W Orford


Get Report Now

Age

Keith William Orford is in his 40s

Keith Has Lived In

Canton, MA
Walpole, MA
Moorpark, CA

Keith's Relatives

Caroline Orford







Keith William Orford



Zodiac SignVirgo



GenderMale



Professional Status
Senior Vice President, Clinical Development at Calithera Biosciences, Inc.



Get Report Now










Want to know more about Keith? Get a comprehensive background report, find full phone numbers, and other contact information when available, all from billions of available public records.
            Continue below for more details about Keith, or use our people search engine to find others.
Get Background Check on Keith William Orford
Get a Criminal Check on Keith William Orford
Get a Public Record Report on Keith William Orford
Get a People Search Report on Keith William Orford


Keith William Orford's Contact Information
Known Cities Lived In
Find out where Keith William Orford has lived as well as Keith William Orford's phone numbers and email addresses.




Keith William Orford Has Lived in 6 States
Massachusetts Address for Keith William Orford


60 M**** S* 

Canton, MA


Has Lived In

Canton, MA
Walpole, MA


Get Full Address Report










Phone Numbers Associated with Keith William Orford

(267) ***-**** - Doylestown, PA 
(781) ***-**** - Canton, MA 
(781) ***-**** - Hingham, MA 


Get Full Phone Report



Email Addresses Associated with Keith William Orford



Get Email Report




Keith William Orford's Education Information
Known Schools Attended
Learn about Keith William Orford's academic history.  Find out which schools Keith William Orford attended, the dates attended as well as the degrees Keith William Orford received.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Keith William Orford Has Attended 4 Schools
Georgetown University 1993 – 2001               Keith William Orford has a MD/PhD in Medicine, Cell Biology, Tumor Biology               
Georgetown University               1993 – 2001               Keith William Orford has a Md/phd, Medicine, Cell Biology, Tumor Biology in Medicine               
Georgetown University               1989 – 1993                              
Georgetown University               1989 – 1993                              


Keith William Orford's Professional Information
Information regarding Keith William Orford's professional history.  Find out previous places Keith William Orford has worked as well as dates employed.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Keith William Orford Has Worked at 9 Places
Company: Calithera Biosciences, Inc.
               Title: Senior Vice President, Clinical Development
Company: Gsk
               Title: Clinical Development Lead, Immuno-oncology and Combinations Dpu
Keith William Orford's Experience
Title: Senior Vice President, Clinical Development
               Company: Calithera Biosciences, Inc.
Job Details
               Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calitheraâ€™s lead product candidate, CB-839, is currently being evaluated in three Phase 1 clinical trials in solid and hematological cancers. CB-1158 is a first-in- class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell suppression by myeloid-derived suppressor cells. Arginase depletes arginine, a nutrient that is critical for the activation, growth and survival of the bodyâ€™s cancer-fighting immune cells, known as cytotoxic T -cells. Calithera is headquartered in South San Francisco, California.
Title: Clinical Development Lead, Immuno-oncology and Combinations Dpu
               Company: Gsk
Job Details

Additional Professional Information on Keith William Orford

 See Keith William Orford's LinkedIn Profile



Keith William Orford's Social Network and Potential Email Matches
Find out potential social network profiles and potential email usernamed for Keith William Orford


Keith William Orford's known Social Networks And Potential Email Matches

Find all of Keith William Orford's Social Network Profiles

Get Full Report

Search Social Networks
Including Facebook, LinkedIn, MySpace, Google, Twitter, Yahoo, Jigsaw, ZoomInfo and more



Potential Email Matches
Keith Orford
Username Matches

                  KeithOrford
                  OrfordKeith
                  Keith.Orford
                  Orford.Keith
                  Keith_Orford
                  Orford_Keith
                  Keith-Orford
                  Orford-Keith
                  KOrford
               


Popular Email Services

@gmail.com
@aol.com
@yahoo.com
@comcast.net
@hotmail.com
@msn.com
@rocketmail.com
@att.net
@sbcglobal.net
@ymail.com
@facebook.com
@mail.com
@bellsouth.net
@live.com
@earthlink.net
@cox.net
@prodigy.net
@me.com
@peoplepc.com
@juno.com
@rediffmail.com
@mindspring.com
@comcast.com
@charter.net
@outlook.com




All trademarks, product names, company names or logos on this page are the property of their respective owners.
Related People Searches
K Orford







         Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual’s eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.
      

About Us
Site Map
About Our Reports
Blog
Help
Contact Us

© 2003 – 2017 PeopleConnect, Inc. d/b/a Intelius. All Rights Reserved.
         Privacy Policy - UPDATED
Terms of Service - UPDATED






What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
                  prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.





















Orford Keith - Calithera Bio Insider Transactions | TipRanks   





Go ProLogin / Sign Up Follow✓Get Real Time TransactionsInsider DetailsOrford KeithCalithera Bio (CALA)SR. VP, CLINICAL DEVELOPMENT Not RankedOrford Keith's PerformanceOrford Keith has not reported any informative transactions and therefore cannot be ranked.How are Insiders Ranked? Orford Keith's Trading Historybased on Form 4 Follow✓Get Real Time TransactionsCompany NameInsider PositionHolding ValueLast TransactionLast Transaction  AmountLast Transaction DateCALACalithera BioSR. VP, CLINICAL DEVELOPMENT-Uninformative Sell$38,817.2Jul 19, 2017Orford Keith has not reported any informative transactions for CALA, therefore, performance cannot be measured. Track Record DateTransactionAmountNo. of SharesPrice per ShareProfitForm 4 Jul 19, 2017 Uninformative Sell $39K 2,120 $16.3 N/A  May 03, 2016 Uninformative Buy (undisclosed) 2,120 $4.7 N/A See All Insider Trading from Today >You May Also LikeMeet our Smart Portfolio. See what top analysts say about your stocks.Get a breakdown of the different strategies based on detected insider trading activity.Find the best performing Analyst in each sector. Follow them so you never miss a recommendation.Related LinksHow can I benefit from Insider Trading? >See the Top 25 Corporate Insiders >Go to Hot Stocks by Insiders >Find which stocks Insiders traded today >Become a TipRanks MemberGet the best Investing Tips & Hacks straight to your emailFree MembershipSubmitInsider Trading Daily NewsletterProfessional day-trading strategy based on predictive insider transactionsAnnual Return: +85.42%Learn More >Powered by
























    Keith Orford | Calithera Biosciences Inc | ZoomInfo.com
Keith Orford 的个人主页 | Facebook

Facebook邮箱或手机号密码忘记帐户？中文(简体)English (US)日本語한국어Français (France)Bahasa IndonesiaPolskiEspañolPortuguês (Brasil)DeutschItalianoMessengerFacebook Lite用户地点游戏位置名人二手市场小组食谱彩色气球Instagram公司简介创建广告创建主页开发者招聘信息隐私权政策Cookie广告选项条款设置活动日志 Facebook © 2017




























Calithera Biosciences Appoints Keith Orford, M.D., Ph.D. To Vice President Of Clinical Development - TheStreet



































































 

 




















Action Alerts PLUS

Access AAPJim Cramer's Best Stocks for 2017Charitable Trust PortfolioMost Recent Trade Alert25 Investing Rules10 Trading Commandments

Real Money

Access RM25 Rules of InvestingJim Cramer's Best Stocks for 201710 CommandmentsStressed Out StocksCramer's Blog

Cramer
Mad Money
ETFs
Futures
Markets
Much More

BanksBiotechRetailTechPersonal FinanceRetirementFinancial Advisor CenterHow to SpendOptionsFixed IncomeVideo










Privacy Policy|Terms of Use© 1996- TheStreet Inc. All rights reserved
















                                DJIA
                            







                                NASDAQ
                            







                                S&P 500
                            






Market Data updated






Sign In




Your Membership(s)








Your Account





Account Preferences


Alerts


Newsletters







Subscribe





Logout



Subscribe

Access insights and guidance from our Wall Street pros. Find the product that's right for you.
Action Alerts PLUS
Action Alerts OPTIONS
Daily Swing Trade
Income Seeker
Quant Ratings
Real Money
Real Money Pro
Stocks Under $10
Top Stocks
Trifecta Stocks
Real Money Pro Portfolio
Chairman's Club
Compare All 
Chatter on the Street













































 








































Calithera Biosciences Appoints Keith Orford, M.D., Ph.D. To Vice President Of Clinical Development






GlobeNewswire



Jan 30, 2015 9:00 AM EST













 


























































    SOUTH SAN FRANCISCO, Calif., Jan. 30, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, announced today the appointment of Dr. Keith Orford, M.D. Ph.D., as Vice President of Clinical Development. He joins the company following a distinguished career in oncology pharmaceuticals development, including senior clinical roles with GlaxoSmithKline (GSK) and Merck. At Calithera, Dr. Orford will be responsible for clinical development of CB-839, its lead oral product candidate in tumor metabolism, as well as subsequent clinical development programs.  "Dr. Orford has joined the Calithera management team at an exciting time for our company as CB-839 progresses through three phase I clinical trials," said Susan Molineaux, Ph.D., President and Chief Executive Officer. "Dr. Orford brings medical and scientific expertise to this important new position, having led the transition of a number of oncology drug candidates from preclinical development through successful clinical trials."  Dr. Orford joins Calithera from GSK where he was the Clinical Development Lead in the Immuno-Oncology and Combinations Development Performance Unit, overseeing the clinical activities on multiple early stage clinical trials with targeted agents and novel immune-based therapies. Prior to GSK, Dr. Orford was at Merck, where he worked on early clinical development programs across oncology and other therapeutic areas. He completed his clinical training in Internal Medicine and postdoctoral work at Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), studying the epigenetic regulation of hematopoietic and embryonic stem cell differentiation, becoming a Research Fellow and then an Instructor at MGH/HMS. Dr. Orford received his undergraduate degree, M.D. and Ph.D. from Georgetown University.  About Calithera   Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera's lead product candidate, CB-839, is currently being evaluated in three Phase 1 clinical trials in solid and hematological cancers. Calithera is headquartered in South San Francisco. For more information about Calithera, please visit www.calithera.com.  Forward Looking Statements  This news release contains forward-looking statements by Calithera that involve risks and uncertainties. These statements include those related to the advancement of Calithera's tumor metabolism and tumor immunology therapeutics through clinical development and the commercialization of Calithera's product candidates. Actual results may differ from Calithera's expectations and important factors that could cause actual results to differ materially. Calithera's product candidates may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's Quarterly Report on Form 10-Q for the period ended September 30, 2014 and other periodic filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances. CONTACT: Jennifer McNealey         ir@Calithera.com         650-870-1071       



 



 










































If you liked this article you might like













Market Needs to Keep Going in One Direction
There is nothing to indicate that this period of chaotic rotation has ended.



Rev Shark

Jul 5, 2017 4:21 PM EDT
























Biotech Movers: Shire Falls on Stem Cell Program Transfer; Calithera, Synergy Up on FDA Approvals
Plus more from the biotechnology world on Wednesday, June 7.



William McConnell

Jun 7, 2017 10:34 AM EDT
























Desire to Add Exposure Leads Indices Higher
The fact that many traders weren't well-positioned for Monday's move up is helping to create one-way action this morning.



Rev Shark

Apr 25, 2017 10:33 AM EDT
























The Best Timeframe Right Now Is the Intraday Trade
Traders recognize that chasing doesn't work when there is so little momentum.



Rev Shark

Apr 20, 2017 10:53 AM EDT








































 











Trending


The Apple iPod Nano and Shuffle Have Officially Died


Check Out the Tesla Model 3's Key Specs as Elon Musk Prepares to Hand Out Keys on Friday


Southwest Shares Just Dropped 50,000 Feet, Thanks Mostly to One Number


Amazon, PayPal, Twitter and 10 Other Companies All Just Taught Me Valuable Lessons


Tesla's Model 3 Arrives on Friday -- Here's Everything You Need to Know











Advertising Partners



 






 






 






 


























 

























 































 


©1996-2017 TheStreet, Inc. All rights reserved.Action Alerts PLUS is a registered trademark of TheStreet, Inc.




Compare Brokers



 







 







 







 







 







 

















Keith Orford - Senior Vice President, Clinical Development at Calithera Biosciences, Inc.



























































                      NEWS HOME
                    

Advertising
Board and Executive Moves
Energy
Health Care
Hedge Funds
M & A
Private Equity
Technology








            You have  
            
9 free profiles

              left this month   
			      

                Start Your Free Trial ➤
              








            Hey, we noticed you're a RelSci Pro subscriber! Would you like to view the page there?
            

                View on RelSci Pro ➤
              




























































































































Email







LinkedIn







Facebook







Google+







Tweet







Reddit





Permalink





Keith Orford
Senior Vice President, Clinical Development at Calithera Biosciences, Inc.



Overview
Relationships Paths
Education Career History Public Holdings 


Keith Orford
Senior Vice President, Clinical Development at Calithera Biosciences, Inc.



 Overview



Age



45
                                  (Born 1972)
                                              




Number of Relationships



                This person is connected to 18 people.
              






 Relationships
              See Details




Susan M. Molineaux

Co-Founder at Calithera Biosciences, Inc.




Hagit Glickman

Head-People & Culture at Calithera Biosciences, Inc.





Jennifer McNealey

Former Senior Director, Investor Relations & Strategy at Calithera Biosciences, Inc.




Mark K. Bennett

Former Senior Vice President, Research at Calithera Biosciences, Inc.





Christopher J. Molineaux

Senior Vice President, Development at Calithera Biosciences, Inc.




Eric B. Sjogren

Senior Vice President, Drug Discovery at Calithera Biosciences, Inc.





Curtis C. Hecht

Senior Vice President, Business & Corporate Development at Calithera Biosciences, Inc.




William D. Waddill

Former Chief Financial Officer, Secretary, Treasurer & Senior Vice President at Calithera Biosciences, Inc.





Jinfu Yang

Clinical Research Director at Calithera Biosciences, Inc.




Noviati Kosasih

Principal at Calithera Biosciences, Inc.







See 8 more listings with RelSci Professional.

Start My Free Trial ➤








See 8 More 


 


 Paths to Keith Orford



            Keith Orford          




 You



 Connections via Relationship Science



 Keith Orford






Sync your contacts to see how you can connect with Keith Orford.

Start My Free Trial ➤








See  More 


 


 Educational Background



 


Georgetown University

                  Georgetown University is a private research university in Washington, D.C. Founded in 1789, it is the oldest Jesuit and Catholic university in the United States. Georgetown's main campus, located in Washington's Georgetown neighborhood, is noted for Healy Hall, a National Historic Landmark in the Romanesque revival style. Georgetown operates a law center on Capitol Hill and auxiliary campuses in Italy, Turkey, and Qatar.                





 Career History



Senior Vice President, Clinical Development

                                    2015 - Current                


Calithera Biosciences, Inc.


                  Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company, which focuses on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.                





 Public Holdings






Restricted data only for RelSci Professional users.

Start My Free Trial ➤








See  More 


 


 Other Affiliations




              Keith Orford is affiliated with
                            Calithera Biosciences, Inc..
            





You've reached your 10 free profiles limit this month.
Upgrade to RelSci Pro today to enjoy unlimited article views and much more!

Start My Free Trial  ➤

Still not convinced? Check out our full listing of features here.












Are you a RelSci Pro Subscriber?

Login to RelSci Pro 
                        ➤


Not a Pro Subscriber? Log in here to manage your alerts









 Keep me signed in.
        

Login  ➤



        Forgot your Password?
    

























 I have read the LexisNexis terms & conditions




Sign Me Up  ➤
















SR. VP, CLINICAL DEVELOPMENT of Calithera Biosciences (NASDAQ:CALA), Orford Keith, sells 2,120 shares worth ,823









































Stay Connected

Latest Posts in RSS

BusinessEntertainmentFeatured NewsFeatured Press ReleaseFinanceHealthLifestyleNationNon FirstPageOriginalPress ReleaseReviewShoppingSportsStocksTechnologyTravelWorld


Latest Comments in RSS


 / 













EmpoweredNews
World News Summary Helping You Stay Informed









Business
Finance
Sports
Entertainment
Health
Technology
Travel
Shopping




Our Writers
About Us
Privacy Policy
Contact Us
Advertise
Press Releases
















SR. VP, CLINICAL DEVELOPMENT of Calithera Biosciences (NASDAQ:CALA), Orford Keith, sells 2,120 shares worth $38,823
According to Calithera Biosciences's most recent Form 4 filing with the SEC dated Jul 19 04:05 PM, company SR. VP, CLINICAL DEVELOPMENT, Orford Keith disclosed selling 2,120 shares at a cost of $18.31. At the time of this transaction (Jul 17), this trade was worth $38,823 in total. As of Jul 17, Orford Keith now owns 6,879 shares in total worth about $113,651.3985. 
For the last few recent trades made by Calithera Biosciences (NASDAQ:CALA) SR. VP, CLINICAL DEVELOPMENT, Orford Keith, we have the following information:







					Posted by  



George Daniels 

					
					on Wednesday July 19 2017, 6:09 PM EDT. 

All trademarks acknowledged. 
Filed under Stocks.

	Comments closed, Trackbacks open.	
 Follow responses: 
RSS 2.0




Comments are closed


 Latest News 
10% Owner of Internap Corporation (NASDAQ:INAP), Park West Asset Management Llc, sells 125,000 shares worth $523,250
Vice President, Sales of Tactile Systems Technology (NASDAQ:TCMD), Rishe Bryan, sells 1,500 shares worth $45,615
10% Owner of Nabriva Therapeutics plc – Ordi (NASDAQ:NBRV), Hbm Healthcare Investments (Ca, sells 20,786 shares worth $218,253
Chief Communications Officer of Netflix (NASDAQ:NFLX), Friedland Jonathan, sells 1,232 shares worth $219,308
Pres., Legal & General Counsel of Salesforce (NYSE:CRM), Weaver Amy E, sells 681 shares worth $60,835
Chief Financial Officer of Civitas Solutions (NYSE:CIVI), Holler Denis M., sells 5,429 shares worth $103,911
EVP, Global Employee Success of Salesforce (NYSE:CRM), Robbins Cynthia G., sells 681 shares worth $60,835
Chairman of the Board and CEO of Salesforce (NYSE:CRM), Benioff Marc, sells 10,000 shares worth $898,709
10% Owner of Upland Software (NASDAQ:UPLD), Wave Systems Corp, sells 18,780 shares worth $428,830
CEO, GWS of CBRE Group Inc ss A (NYSE:CBG), Concannon William F, sells 4,480 shares worth $170,288

 


News Categories 
Business (7)

Stocks (15,297)



Entertainment (1,297)

Featured News (3,486)

Featured Press Release (250,636)

Finance (309)

Health (653)

Lifestyle (19)

Nation (90)

Non FirstPage (2)

Original (47)

Press Release (17)

Review (1)

Shopping (267)

Sports (613)

Technology (194)

Travel (286)

World (1,367)


  Featured Press Releases 
Latest News On Audiophile Headphone Industry Global Research Report 2017-2021
United States Membrane Pumps Revenue and Growth Rate 2017-2022
Global Disinfectants Industry Forecast to 2021 with Sales, Sales Price and Gross Margin Analysis
United States Diaphragm Pumps Revenue and Growth Rate 2017-2022
India Fire Safety Equipment Market 2017 Industry Trend and Forecast 2021
Global Digital Printing Machine Market Forecast to 2021 with Competitive Landscape Analysis and Key Companies Profile
Global Diatom Mud Market Forecast to 2021: Sales, Sales Price, Gross Margin, Application, Consumption Forecast and Key Companies Profile
Global Dialysis Equipment Market Analysis by Application, Product Types and Regions with Forecast to 2022
Global Diagnostic ECG Industry Major Players Product Capacity and Production Analysis (Units) (2012-2017)
Global Dental Ultrasonic Scaler Industry Forecast to 2021 with Sales, Sales Price and Gross Margin Analysis







Business
Finance
Sports
Entertainment
Health
Technology
Travel
Shopping
 

About Us
Contact Us
Privacy Policy
Advertise
Press Releases
Terms Of Service
 
Log in 















ORFORD KEITH Top Holdings  

































WhaleWisdom









Search All
Search 13F Filers Only
Search SEC Filer
Search Stocks Only
Search Mgmt Inv. Cos Only
ETFs Only
Search Active




















                      ORFORD KEITH
                    

•   SOUTH SAN FRANCISCO, CA
                      
How do I update this listing?




                                             Orford Keith is based out of South San Francisco.    WhaleWisdom has at least 1 insider transactions (Form 3,4,5) in our database for Orford Keith. 
                                           














Summary
13D/G
Insider (Form 4)



   Create Email Alert
 




×
Email Notification.







                   ***Log In or
                   Sign-up
                   to see more advanced email alert options such as selecting any type of
                   SEC form, multiple filers or classes of filers, and much more.***
                 

                    ...or to simply have an email sent to you whenever we receive a new
                           13F filing from ORFORD KEITH, enter your
                    email address below and choose 'Submit'.
                

Your email:








Cancel














Contact Info




orford keith


CALITHERA BIOSCIENCES

SOUTH SAN FRANCISCO
CA
                                                        
                                                    94080


                                                      Business Phone:
                                                      650-870-1000
SEC SIC CODE:2834-PHARMACEUTICAL PREPARATIONS







Recent SEC Filings




4 filed on 07/19/2017
4 filed on 12/01/2016
3 filed on 05/03/2016
4 filed on 05/03/2016
















Schedule 13D and 13G events since 03/31/2017

Subscription required



 
Form 4 - Non-derivative Insider Transactions Since 03/31/2017
Loading...








Elevate your investments
Try it for free



















Keith


 















 






















Login  |   Register


 


 
 
 
 
 
 
 
 
 


  
















WELCOME

Welcome.  I hope you approve of the new-look website. As wilth all such things it is constantly changing and I will be increasingly adding new material.

LATEST NEWS
New e-mail addressHello everyone and there is plenty of news but not enough time to put it on the site! There will be some up-to-date features appearing very soon.
In the meantiRead More







                	 Copyright © 2017 Keith Offord  / 
                    Terms & Conditions  / 
                    Privacy Policy  / 
                    Sitemap









Keith


 















 






















Login  |   Register


 


 
 
 
 
 
 
 
 
 


  
















WELCOME

Welcome.  I hope you approve of the new-look website. As wilth all such things it is constantly changing and I will be increasingly adding new material.

LATEST NEWS
New e-mail addressHello everyone and there is plenty of news but not enough time to put it on the site! There will be some up-to-date features appearing very soon.
In the meantiRead More







                	 Copyright © 2017 Keith Offord  / 
                    Terms & Conditions  / 
                    Privacy Policy  / 
                    Sitemap







